GUFICBIOGufic Biosciences Ltd.

₹366.25+0.30%

Market Cap

₹3,665.83 Cr

Stock P/E

59.26

ROCE

13.48%

ROE

12.29%

Book Value

₹61.23

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
We shifted our sales teams to concentrate on hospitals with greatest prescribing potential.
•
This entry strategy allowed us to confirm product reliability before scaling. This will be an essential product line given the shortages in this product segment from time to time.

NEGATIVES

•
Indore capitalization increases fixed costs and delays EBITDA breakeven; margins pressured in near term.
•
Pricing erosion in key APIs is reducing rupee margins; bottoming out seen late 2024.

Peers Summary

Sector Leader

Gufic Biosciences Ltd. shows weaker metrics compared to its peers in terms of growth and profitability. However, it has a relatively low debt-to-equity ratio, indicating a more stable financial position. Companies like Cipla and Dr. Reddy's stand out as strong performers, while Gufic remains a value pick in a competitive environment.

Key Points

• Gufic has a low debt-equity ratio of 0.5953 but lacks growth in revenue and profitability metrics.
• Cipla and Dr. Reddy's are standout performers with strong profitability and reasonable valuations.
• Sun Pharma and Divi's Laboratories are showing high valuations and mixed growth, making them potentially overvalued.

Top Performers

Cipla Ltd.

Strong revenue growth (YoY: 13.28%), high ROE (16.63%), and attractive PE ratio (23.73).

Dr. Reddy's Laboratories Ltd.

High profitability with ROE (21.76%) and low PE (15.50), making it a strong value pick.

Mankind Pharma Ltd.

Impressive revenue growth (YoY: 18.12%) and solid profitability metrics.

Explore

Watchlists

Command Palette